Fluorene compound and pharmaceutical use thereof
US-2015329491-A1 · Nov 19, 2015 · US
Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
US10183013B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10183013-B2 |
| Application number | US-201615359102-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2016 |
| Priority date | Nov 5, 2012 |
| Publication date | Jan 22, 2019 |
| Grant date | Jan 22, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer in a mammal, the method comprising administering to the subject a therapeutically effective amount of NTW-3729, wherein NTW-3729 is a compound defined by the structure: and wherein the cancer is selected from the group consisting of lung cancer, and pancreatic cancer. 2. The method of claim 1 , wherein NTW-3729 is administered with one or more other active agents. 3. The method of claim 1 , wherein NTW-3729 is administered with a carrier. 4. A method for reducing signal transduction by the Hedgehog pathway in cells comprising contacting the cells with NTW-3729, wherein NTW-3729 is a compound defined by the structure: 5. The method of claim 4 , wherein the cells are in vivo. 6. The method of claim 4 , wherein the cells are human. 7. The method of claim 1 , wherein the cancer is lung cancer. 8. The method of claim 1 , wherein the cancer is pancreatic cancer. 9. The method of claim 1 , wherein the mammal is human. 10. The method of claim 1 , wherein NTW-3729 reduces signal transduction by the hedgehog pathway. 11. The method of claim 2 , wherein the one or more additional active agents comprises paclitaxel. 12. The method of claim 1 , wherein the NTW-3729 is administered orally. 13. The method of claim 1 , wherein the NTW-3729 is administered in a dosage of between 0.01-100 mg/kg body weight/day.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
1,2-Thiazines; Hydrogenated 1,2-thiazines · CPC title
Six-membered rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10183013B2 cover?
- The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
- Who is the assignee on this patent?
- Nantbioscience Inc, Nant Holdings Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/425. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).